BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Quotes and News

BioMarin Pharmaceutical Inc. (BMRN) 64.00 -0.49

Price Open:	65.10	Day's Range:	36.30000 - 71.50000
Price Close:	64.50	52wk Range:	30.06 - 71.50000
Price Day Change:	-0.49	Volume:	1,459,698
Price % Change:	-0.76	Market Cap:	8.898B
Bid:	60.01000	PE Ratio:	0
Ask:	64.00000	EPS Diluted:	-1.054

Trade BMRN NOW!

The Latest On BMRN

BioMarin Submits CTA for BMN-190 for Batten Disease 4/1/13 9:03am

Biomarin Closes Added Partial Exchange of Convertible Notes Due 2017 3/25/13 9:01am

UPDATE: Jefferies Raises PT on BioMarin Pharmaceutical as BMN-701 Moves Forward 3/20/13 11:49am

UPDATE: Wedbush Raises PT on BioMarin Pharmaceuticals on Positive Phase 2 Data 3/20/13 10:41am

UPDATE: Piper Jaffray Raises PT on BioMarin Pharmaceutical on Positive Trial Results 3/20/13 9:26am

UPDATE: Deutsche Bank Raises PT on BioMarin Pharmaceuticals on Pipeline Outlook 3/20/13 8:17am

BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Trials, Sees Phase 2/3 Switching Trial by End of 2013 3/19/13 4:22pm

BioMarin Reports Statistically Significant Changes in Kuvan Responding PKU Patients 2/19/13 10:05am

UPDATE: Canaccord Genuity Raises PT to $71 on BioMarin Pharmaceutical on Upcoming Catalysts 2/12/13 2:22pm

UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts 1/22/13 2:47pm

BioMarin Buys Zacharon Pharma for $10M 1/7/13 10:08am

J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin Pharmaceutical 1/2/13 3:14pm

Press Releases

BioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCO 5/16/13 GlobeNewswire

BioMarin to Present at the UBS Global Healthcare Conference 5/14/13 GlobeNewswire

BioMarin to Present at the Baird Growth Stock Conference 5/2/13 GlobeNewswire

BioMarin Announces First Quarter 2013 Financial Results 4/25/13 GlobeNewswire

BioMarin Submits Vimizim MAA to EMA for the Treatment of MPS IVA 4/24/13 GlobeNewswire

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 4/18/13 GlobeNewswire

BioMarin to Host First Quarter 2013 Financial Results Conference Call and Webcast on Thursday, April 25 at 5:00 p.m. ET 4/4/13 GlobeNewswire

BioMarin Submits CTA for BMN-190 for Batten Disease 4/1/13 GlobeNewswire

BioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA 4/1/13 GlobeNewswire

BioMarin Completes Additional Partial Exchange of Convertible Notes Due 2017 for Common Stock 3/25/13 GlobeNewswire

BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development 3/19/13 GlobeNewswire

BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 3/19/13 GlobeNewswire

Get the latest BMRN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for BioMarin Pharmaceutical Inc. stock price.

Partner Headlines

BioMarin Widens Loss, Maintains View - Analyst Blog 4/29/13

BioMarin Attains 52-Week High - Analyst Blog 4/11/13

BioMarin Files CTA for BMN-190 - Analyst Blog 4/3/13

BMRN Seeks US Approval of Vimizim - Analyst Blog 4/2/13

Data on BioMarin's BMN-701 - Analyst Blog 3/21/13

Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 11,000 Shares 3/4/13

Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,500 Shares 2/28/13

BioMarin Reports Wider Loss - Analyst Blog 2/22/13

Positive Data from BMRN's PKU-016 - Analyst Blog 2/20/13

Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares 2/5/13

Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime sells 14,000 Shares 1/24/13